About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

BUY ERX OR THE KITTY GETS IT

Laurie i wouldn't read much into 3:2 sale on 10 mil share as this is only 30,000 hardley anything compared with it's market cap.

WAS IT THIS QUIET THE DAY BEFORE LAST YEARS RESULTS?

yes. and guess what the SP rocketed ;-)

nice to see a repeat performance

looking at the chart for last year it went up mid Jan to .34

yes but we are going to get significant news and today i was wished a very happy christmas by JP.. do you think he is trying to tell me something in code..

i,e, you will be well happy mate.. dont worry!!! ;-)

i think he is saying that..

500,000 just went through well above the sp price @ 0.32p?

there is a party going on over at the darkside, your invited

RNS is out! First impression is a fund raising in April 2007 and no sign of any milestone payments.

Over to you Potatohead!

Key points

EiRx stands to earn milestones and royalties on the successful development of ZYC300. A similar success-based milestone arrangement pertains to the Company's licensing of drug targets to OSI Pharmaceuticals (NASDAQ: OSIP). The Board will update the market if and when such milestones are reached.

EiRx and Almac Diagnostics view the signing of this agreement the first phase of a strategic alliance that is expected to expand as the companies work together to develop enhanced treatments for colorectal cancer.


ERX entered into an agreement with bioMerieux SA, the leading international diagnostics group headquartered in France. Should we enjoy success in our collaborative technical programme we would expect to progress to technology licensing and ultimately to generate milestone payments and revenues from the development of new cancer diagnostics products by bioMerieux.

Efficacy of ERX3722 in breast cancer model
These molecules are currently undergoing further development and optimization for the treatment of breast cancer; a market estimated to be worth $6.2 billion per annum. Other cancer indications will also be sought for these molecules and/or their optimized derivatives.

EiRx's main discovery effort aims to identify novel cancer kinase inhibitors, and several recent third-party licensing deals indicate the impressive valuations being placed on such products at the late preclinical stage. These include Rigel's licensing of the aurora kinase inhibitor R763 to Serono (total potential value of $160M, with $25M upfront), CGI's licensing of the multi-kinase inhibitor CGI1842 to Genentech (total potential value of $500M, with $25M upfront), Plexxikon's licensing of the PLX4032 inhibitor of mutant B-Raf kinase to Roche (total potential value $660M, with $40M upfront) and Piramed's licensing of its PI3-kinase inhibitor programme to Genentech (total potential value of $230M).

I believe this recent licensing activity in EiRx's chosen field bodes well for
EiRx's future prospects, but also indicates the stage of development at which
the Company can expect to secure a significant license deal.

Thanks for the recap driver, more news tomorrow you think ??

Driver do you think the share price will drop or go up the the result reported?

Marcel
Its the new funds that is the problem punters on the other side want jam right now, IMO erx has a lot going on and payments could come at any time or a development announcement that will see the sp surge I will not be selling just adding on any dips ERX looks like a good long term play I was buying at .17 and would do so again if it ever gets there.

Thanks for your opion

Have read the rns and the part that stood out for me was this....

EiRx's main discovery effort aims to identify novel cancer
kinase inhibitors, and several recent third-party licensing deals indicate the
impressive valuations being placed on such products at the late preclinical
stage. These include Rigel's licensing of the aurora kinase inhibitor R763 to
Serono (total potential value of $160M, with $25M upfront), CGI's licensing of
the multi-kinase inhibitor CGI1842 to Genentech (total potential value of $500M,
with $25M upfront), Plexxikon's licensing of the PLX4032 inhibitor of mutant
B-Raf kinase to Roche (total potential value $660M, with $40M upfront) and
Piramed's licensing of its PI3-kinase inhibitor programme to Genentech (total
potential value of $230M).

I believe this recent licensing activity in EiRx's chosen field bodes well for
EiRx's future prospects, but also indicates the stage of development at which
the Company can expect to secure a significant license deal. To reach the late preclinical stage common to the recent license deals listed above, EiRx will
require a minimum of two to three years' further research and development.

RichF
And your point is.

Raising more funding is not a negative, if that is what is needed for further development them let them raise it we will benefit in the end.


Bioprogress recently raised funds with a placing at 50p in sept they stand at nearly 70p

Also ASM raised 26.3m and we didn't even know it was coming, the sp lost a few points now it's on the up.

London UK, 15 December 2006 Antisoma plc (LSE:ASM, US OTC: ATSMY)
today announces that it has raised approximately 26.3 million before
expenses.

I think the MM will milk the share holders trying to bail out this morning.

Where's the potato head gone! Would be interesting to hear their comments.